title: Editorial commentary: treatment of Kaposi sarcoma in the highly active antiretroviral therapy era.
authors.forename: N
authors.initials: N
authors.lastname: Dupin
authors.forename: P
authors.initials: P
authors.lastname: Del Giudice
mesh_terms: D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use; D023241:Antiretroviral Therapy, Highly Active; D004317:Doxorubicin / Q000031:analogs & derivatives / Q000627:therapeutic use; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy*; D019288:Herpesvirus 8, Human; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000150:complications / Q000821:virology; D011092:Polyethylene Glycols / Q000627:therapeutic use; D012514:Sarcoma, Kaposi / Q000150:complications / Q000188:drug therapy / Q000821:virology*
chemical_list: D000903:Antibiotics, Antineoplastic; C506643:liposomal doxorubicin; D011092:Polyethylene Glycols; D004317:Doxorubicin